Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
Johns Hopkins Bayview Medical Center Center for Chemical Dependence
mi
from
Baltimore, MD
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
Johns Hopkins Bayview Medical Center Center for Chemical Dependence
mi
from
Baltimore, MD
Click here to add this to my saved trials
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
Boston University School of Medicine
mi
from
Boston, MA
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
New York University Mental Health and Addictive Disorders Research Program
mi
from
New York, NY
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
New York University Mental Health and Addictive Disorders Research Program
mi
from
New York, NY
Click here to add this to my saved trials
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
Cincinnati Addiction Research Center (CinARC)
mi
from
Cincinnati, OH
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
Cincinnati Addiction Research Center (CinARC)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
Dayton Veterans Affairs Medical Center
mi
from
Dayton, OH
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
Dayton Veterans Affairs Medical Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated:  3/14/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Vigabatrin for Treatment of Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Status: Enrolling
Updated: 3/14/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sleep Disorders Management, Health and Safety in Police
Sleep Disorders Management, Health and Safety in Police
Status: Enrolling
Updated:  3/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Sleep Disorders Management, Health and Safety in Police
Sleep Disorders Management, Health and Safety in Police
Status: Enrolling
Updated: 3/15/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Medical University of South Carolina
mi
from
Charleston, SC
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Sleep Medicine Associates of Texas
mi
from
Dallas, TX
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Sleep Medicine Associates of Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Swedish Health Services
mi
from
Seattle, WA
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Swedish Health Services
mi
from
Seattle, WA
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
California Sleep Institute
mi
from
Palo Alto, CA
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
California Sleep Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Clinical Research Group of St. Petersburg, Inc.
mi
from
St Petersburg, FL
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Clinical Research Group of St. Petersburg, Inc.
mi
from
St Petersburg, FL
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
University of South Florida
mi
from
Tampa, FL
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Advanced ENT
mi
from
Atlanta, GA
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Advanced ENT
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Borgess Research Institute
mi
from
Portage, MI
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Borgess Research Institute
mi
from
Portage, MI
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
North Memorial Medical Center
mi
from
Maple Grove, MN
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
North Memorial Medical Center
mi
from
Maple Grove, MN
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
St. Cloud ENT
mi
from
St. Cloud, MN
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
St. Cloud ENT
mi
from
St. Cloud, MN
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
University Hospitals / Case Western Reserve
mi
from
Cleveland, OH
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
University Hospitals / Case Western Reserve
mi
from
Cleveland, OH
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
University of Pittsburgh Medical Center; Montefiore
mi
from
Oakland, PA
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
University of Pittsburgh Medical Center; Montefiore
mi
from
Oakland, PA
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Froedtert Memeorial Hospital
mi
from
Milwaukee, WI
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Froedtert Memeorial Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated:  3/15/2016
Deparment of Pulmonology Head and Neck Surgery, Universitair Ziekenhuis Antwerpen
mi
from
Antwerp,
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea
Status: Enrolling
Updated: 3/15/2016
Deparment of Pulmonology Head and Neck Surgery, Universitair Ziekenhuis Antwerpen
mi
from
Antwerp,
Click here to add this to my saved trials
Fire Fighter Fatigue Management Program: Operation Fight Fatigue
Fire Fighter Fatigue Management Program: Operation Fight Fatigue
Status: Enrolling
Updated:  3/15/2016
Division of Sleep Medicine; Brigham and Women's Hospital
mi
from
Boston, MA
Fire Fighter Fatigue Management Program: Operation Fight Fatigue
Fire Fighter Fatigue Management Program: Operation Fight Fatigue
Status: Enrolling
Updated: 3/15/2016
Division of Sleep Medicine; Brigham and Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated:  3/16/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated: 3/16/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated:  3/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated: 3/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated:  3/16/2016
University of Massachusetts
mi
from
Worcester, MA
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated: 3/16/2016
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated:  3/16/2016
University of Salzburg
mi
from
Salzburg,
Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients
Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients
Status: Enrolling
Updated: 3/16/2016
University of Salzburg
mi
from
Salzburg,
Click here to add this to my saved trials
Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery
Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated:  3/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery
Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery: A Randomized Controlled Trial
Status: Enrolling
Updated: 3/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Status: Enrolling
Updated:  3/16/2016
Broward Research Group
mi
from
Hollywood, FL
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Status: Enrolling
Updated: 3/16/2016
Broward Research Group
mi
from
Hollywood, FL
Click here to add this to my saved trials
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Status: Enrolling
Updated:  3/16/2016
Miami Research Associates
mi
from
Miami, FL
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
Status: Enrolling
Updated: 3/16/2016
Miami Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Cincinnati, OH
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Richmond, VA
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Mobile, AL
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
DeLand, FL
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
DeLand, FL
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Orlando, FL
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Tampa, FL
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Sunset, LA
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Sunset, LA
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
St. Charles, MO
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Charlotte, NC
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Rock Hill, SC
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Seneca, SC
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Newport News, VA
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Concepción,
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Concepción,
Click here to add this to my saved trials
Mindfulness Based Stress Reduction in COPD
Mindfulness Based Stress Reduction in COPD
Status: Enrolling
Updated:  3/17/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Mindfulness Based Stress Reduction in COPD
Mindfulness Based Stress Reduction in COPD
Status: Enrolling
Updated: 3/17/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Non-invasive Intervention for Apnea of Prematurity
Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.
Status: Enrolling
Updated:  3/17/2016
Ronald Reagan Medical Center - UCLA
mi
from
Los Angeles, CA
Non-invasive Intervention for Apnea of Prematurity
Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.
Status: Enrolling
Updated: 3/17/2016
Ronald Reagan Medical Center - UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials